StockData
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS) stock

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.17−0.43 (-4.06%)

Close on Nov 17, 2026Market cap $855.51MP/E –Yield –

Corvus Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Corvus Pharmaceuticals's price to book ratio was 4.3× on Nov 11, 2026, against 9.5× a year earlier. Over the last 5 years it ranged from 0.5× to 45.8×, with a median of 3.2×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.3×−3.7
2025Dec 31, 20258.0×−19.0
2024Dec 31, 202427.0×+25.0
2023Dec 29, 20231.9×+1.3
2022Dec 30, 20220.6×−0.5
2021Dec 31, 20211.1×−1.3
2020Dec 31, 20202.4×+0.4
2019Dec 31, 20192.0×+1.1
2018Dec 31, 20180.9×−1.4
2017Dec 29, 20172.3×+0.2
2016Dec 30, 20162.1×–

More Corvus Pharmaceuticals figures

See a number that looks wrong?